ArticleTherapeutic advances in medical oncology2021
Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Association between immune checkpoint inhibitors and the risk and prognosis of uveitis: a meta-analysis.Frontiers in immunology · 2026Pooled it
- Acral lentiginous melanoma metastases to the vitreous masquerading as uveitis: A case report.American journal of ophthalmology case reports · 2026Article
- Steroid-sparing strategies for managing immune-related adverse events.Journal for immunotherapy of cancer · 2026Review
- Ocular adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database.Frontiers in pharmacology · 2026Article
- A case of severe bilateral corneal ulcer associated with sintilimab therapy: case report and literature review.Frontiers in pharmacology · 2026Article
- Can Immune Checkpoint Modulation Redefine Ocular Immunotherapy? Emerging Mechanisms, Challenges, and Translational Opportunities-A Comprehensive Review.Investigative ophthalmology & visual science · 2025Review
- Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications.Clinical optometry · 2025Review
- Case Report: Tislelizumab-induced panuveitis: a report of two cases.Frontiers in pharmacology · 2025Article
- Article
- Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review.Biomedicines · 2024Review
- Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.Diagnostics (Basel, Switzerland) · 2024Review
- Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature.Journal of ophthalmic inflammation and infection · 2023Review
- Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.Journal of ophthalmic inflammation and infection · 2023Article
- Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors.Frontiers in immunology · 2023Article
- Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center.Journal of immunotherapy and precision oncology · 2022Article
- Ocular Inflammation Induced by Immune Checkpoint Inhibitors.Journal of clinical medicine · 2022Article
- Review
- Immunotherapy-induced retinopathy mimicking cancer associated retinopathy.American journal of ophthalmology case reports · 2022Article
- Use of fluocinolone acetonide intravitreal implant to manage chronic panuveitis for long-term inflammatory control without interfering with systemic immunity.Digital journal of ophthalmology : DJO · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition and early intervention are essential because the degree of tissue damage may be disproportionate to the symptoms, and lack of appropriate treatment risks permanent loss of vision. International guidelines on managing ocular IrAEs provide limited advice only. Importantly, local interventions can be effective and may avoid the need for systemic corticosteroids, thereby permitting the continuation of CPIs. We present a single institution case series of eight affected patients managed by our multidisciplinary team. Consistent with previously published series and case reports, we identified anterior uveitis as the most common ocular IrAE associated with CPIs requiring intervention. Based on our experience, as well as published guidance, we generated a simple algorithm to assist clinicians efficiently manage patients developing ocular symptoms during treatment with CPIs. In addition, we make recommendations for optimising treatment of uveitis and address implications for ongoing CPI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.